{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-003726","form_type":"8-K","ticker":null,"cik":"0001429560","company_name":"TREVENA INC","filed_at":"2026-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.063619+00:00","generated_at":"2026-05-16T10:24:07.788481+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Trevena terminates royalty loan by assigning China license to R-Bridge; all debt discharged","bullets":["Agreement dated Jan 9, 2026 with R-Bridge, Nhwa: royalty loan obligations released in exchange for China license rights (except milestones).","Trevena transfers all rights under China License Agreement to R-Bridge; Nhwa consents, future royalties (except milestones) paid to R-Bridge.","Loan Agreement and all security interests terminated; Trevena SPV1, SPV2, Royalty LLC released from obligations.","China License Agreement term extended to 10 years after first commercial sale (June 30, 2033), with possible renewal.","Trevena discontinued US commercialization of Olinvyk; covenants to enter new safety data exchange if resumed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-003726","json":"https://secwatch.observer/filing/0001104659-26-003726.json","markdown":"https://secwatch.observer/filing/0001104659-26-003726.md","text":"https://secwatch.observer/filing/0001104659-26-003726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429560/000110465926003726/0001104659-26-003726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429560/000110465926003726/tm263115d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:24:07.788481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92a811928d6e727caa561acaa00dd9bc187e663c","claim":"TREVENA INC terminated License Agreement with Jiangsu Nhwa Pharmaceutical Co. Ltd. and R-Bridge Investment Four Pte. Ltd. (effective 2026-01-09).","evidence_excerpt":"On January 9, 2026, Trevena, Inc., Trevena SPV2 LLC, Trevena SPV1 LLC, and Trevena Royalty LLC (collectively the “Company”) entered into an Assignment and Release Agreement (the “Agreement) with Jiangsu Nhwa Pharmaceutical Co. Ltd. (“Nhwa”) and R-Bridge Investment Four Pte. Ltd., (the “Lender”) whereby the Lender agreed to terminate and release the Company from all obligations","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429560/000110465926003726/0001104659-26-003726-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Jiangsu Nhwa Pharmaceutical Co. Ltd. and R-Bridge Investment Four Pte. Ltd."},{"label":"Effective","value":"2026-01-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}